These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 8864678)

  • 1. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
    Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
    Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
    Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
    Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction.
    Lord RV; O'Grady R; Sheehan C; Field AF; Ward RL
    J Gastroenterol Hepatol; 2000 Jul; 15(7):730-6. PubMed ID: 10937677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 is frequently mutated in Barrett's metaplasia of the intestinal type.
    Campomenosi P; Conio M; Bogliolo M; Urbini S; Assereto P; Aprile A; Monti P; Aste H; Lapertosa G; Inga A; Abbondandolo A; Fronza G
    Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):559-65. PubMed ID: 8827361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk in Barrett's oesophagus.
    Dias Pereira A; Suspiro A; Chaves P
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.
    Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
    Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal and pancreatic metaplasia at the esophagogastric junction in patients without Barrett's esophagus.
    Polkowski W; van Lanschot JJ; ten Kate FJ; Rolf TM; Polak M; Tytgat GN; Obertop H; Offerhaus GJ
    Am J Gastroenterol; 2000 Mar; 95(3):617-25. PubMed ID: 10710048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barrett's oesophagus: the new endoscopic modalities have a future.
    Deviere J
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
    Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
    Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's oesophagus: from metaplasia to dysplasia and cancer.
    Fléjou JF
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i6-12. PubMed ID: 15711008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrett's oesophagus--a pathologist's view.
    Fléjou JF; Svrcek M
    Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 gene mutations in Barrett's epithelium and esophageal cancer.
    Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
    Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
    Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
    Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.